10
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Evaluación de dos marcas comerciales de pruebas de ELISA para el diagnóstico de HTLV-1 frente a muestras peruanas Translated title: Evaluation of two brands of test of ELISA for the diagnosis of HTLV-1 against Peruvian samples

      rapid-communication

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Resumen Por ser el Perú un país endémico de HTLV-1, es importante conocer la confiabilidad de las marcas comerciales para el diagnóstico más usadas en nuestro país. En el presente estudio, evaluamos dos marcas comerciales de pruebas de ELISA (Biokit y Wantai) para la detección de anticuerpos contra HTLV-1 frente a muestras peruanas. Ambas marcas comerciales fueron evaluadas frente a 242 sueros: 123 positivos a HTLV-1 y 119 negativos a HTLV-1 (referencia: inmunoblot). Se estimaron los parámetros de precisión diagnóstica. La sensibilidad, especificidad, VPP, VPN e índice de validez de Biokit fueron: 100%, 93,2%, 93,8%, 100%, 96,6%; respectivamente y de Wantai fue de 99,1% para todos los parámetros. Concluimos, que la marca Biokit fue la más adecuada para ser usada en el Laboratorio de Referencia Nacional de Virus de Transmisión Sexual, VIH/SIDA de Perú.

          Translated abstract

          Abstract As Peru is endemic to HTLV-1, it is important to know the reliability of the most used screening trademarks in our country. In the present study, we evaluated two brands of ELISA (Biokit and Wantai) for the detection of antibodies against HTLV-1/2 against Peruvian samples. Both brands were evaluated against 242 sera: 123 positive for HTLV-1 and 119 negative for HTLV-1 (Reference: Immunoblot). We estimated diagnostic accuracy parameters. The sensitivity, specificity, PPV, NPV and validity index of Biokit were: 100%, 93.2%, 93.8%, 100%, 96.6%; respectively and Wantai were 99.1% for all parameters. We conclude that the Biokit brand is the most suitable for use in the National Reference Laboratory of Sexually Transmitted Viruses HIV/AIDS, Peru.

          Related collections

          Most cited references16

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Epidemiological Aspects and World Distribution of HTLV-1 Infection

          The human T-cell leukemia virus type 1 (HTLV-1), identified as the first human oncogenic retrovirus 30 years ago, is not an ubiquitous virus. HTLV-1 is present throughout the world, with clusters of high endemicity located often nearby areas where the virus is nearly absent. The main HTLV-1 highly endemic regions are the Southwestern part of Japan, sub-Saharan Africa and South America, the Caribbean area, and foci in Middle East and Australo-Melanesia. The origin of this puzzling geographical or rather ethnic repartition is probably linked to a founder effect in some groups with the persistence of a high viral transmission rate. Despite different socio-economic and cultural environments, the HTLV-1 prevalence increases gradually with age, especially among women in all highly endemic areas. The three modes of HTLV-1 transmission are mother to child, sexual transmission, and transmission with contaminated blood products. Twenty years ago, de Thé and Bomford estimated the total number of HTLV-1 carriers to be 10–20 millions people. At that time, large regions had not been investigated, few population-based studies were available and the assays used for HTLV-1 serology were not enough specific. Despite the fact that there is still a lot of data lacking in large areas of the world and that most of the HTLV-1 studies concern only blood donors, pregnant women, or different selected patients or high-risk groups, we shall try based on the most recent data, to revisit the world distribution and the estimates of the number of HTLV-1 infected persons. Our best estimates range from 5–10 millions HTLV-1 infected individuals. However, these results were based on only approximately 1.5 billion of individuals originating from known HTLV-1 endemic areas with reliable available epidemiological data. Correct estimates in other highly populated regions, such as China, India, the Maghreb, and East Africa, is currently not possible, thus, the current number of HTLV-1 carriers is very probably much higher.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Human T-lymphotropic virus type 1 infection is frequent in rural communities of the southern Andes of Peru.

            To evaluate the presence of human T-lymphotropic virus type 1 (HTLV-1) infection in isolated rural communities in the southern Andes of Peru.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Veinte años de investigación sobre HTLV-1 y sus complicaciones médicas en el Perú: Perspectivas generales

              El virus linfotrópico humano tipo 1 (HTLV-1 [human T-lymphotropic virus]) es un retrovirus con amplia distribución mundial. Pertenece a la familia Retroviridae y a la subfamilia Oncovirinae. Es un virus linfotrópico que compromete principalmente linfocitos CD4. El HTLV-1 está relacionada como agente etiológico de la leucemia/linfoma de células T del adulto (LLTA) y de la mielopatía/paraparesia espástica tropical (M/PPET).
                Bookmark

                Author and article information

                Journal
                rci
                Revista chilena de infectología
                Rev. chil. infectol.
                Sociedad Chilena de Infectología (Santiago, , Chile )
                0716-1018
                December 2020
                : 37
                : 6
                : 780-783
                Affiliations
                [1] Lima Asunción orgnameInstituto Nacional de Salud orgdiv1Centro Nacional de Salud Pública orgdiv2Laboratorio de Referencia Nacional Virus de Transmisión Sexual VIH/SIDA Paraguay
                Article
                S0716-10182020000600780 S0716-1018(20)03700600780
                130446b7-8b11-46c3-985f-7972b7746bcc

                This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

                History
                : 20 November 2020
                : 05 March 2020
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 16, Pages: 4
                Product

                SciELO Chile

                Categories
                COMUNICACION BREVE

                HTLV-1,Wantai,Biokit,ELISA
                HTLV-1, Wantai, Biokit, ELISA

                Comments

                Comment on this article

                Similar content319

                Cited by4

                Most referenced authors106